EUVIMEDEUVIMED entdecken
MetaanalyseÜbersichtsarbeit

The diagnostic performance of micro-RNA and metabolites in lung cancer: A meta-analysis

Mona Mlika, Mohamed Majdi Zorgati, Mehdi Abdennadher, Imen Bouassida, Faouzi Mezni, Ali Mrabet

Asian Cardiovascular and Thoracic Annals · 2024

DOI: 10.1177/02184923231215538 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Asian Cardiovascular and Thoracic Annals, 2024. Verfasst von Mona Mlika und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Center of Traumatology and Major Burns, Ben Arous, Tunis, Tunisia. Hauptthemen laut MEDLINE: MicroRNAs, Lung Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 100 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The diagnosis of lung cancer is based on the microscopic exam of tissue or liquid. During the recent decade, many biomarkers have been pointed to have a potential diagnostic role. These biomarkers may be assessed in blood, pleural effusion or sputum and they could avoid biopsies or other risky procedures. The authors aimed to assess the diagnostic performances of biomarkers focusing on micro-RNA and metabolites.

Methods

This meta-analysis was conducted under the PRISMA guidelines during a nine-year-period (2013–2022). the Meta-Disc software 5.4 (free version) was used. Q test and I 2 statistics were carried out to explore the heterogeneity among studies. Meta-regression was performed in case of significant heterogeneity. Publication bias was assessed using the funnel plot test and the Egger's test (free version JASP).

Results

According to our inclusion criteria, 165 studies from 79 articles were included. The pooled SEN, SPE and dOR accounted, respectively, for 0.76, 0.79 and 13.927. The AUC was estimated to 0.859 suggesting a good diagnostic accuracy. The heterogeneity in the pooled SEN and SPE was statistically significant. The meta-regression analysis focusing on the technique used, the sample, the number of biomarkers, the biomarker subtype, the tumor stage and the ethnicity revealed the biomarker number ( p = 0.009) and the tumor stage ( p = 0.0241) as potential sources of heterogeneity.

Conclusion

Even if this meta-analysis highlighted the potential diagnostic utility of biomarkers, more prospective studies should be performed, especially to assess the biomarkers’ diagnostic potential in early-stage lung cancers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MicroRNAsLung NeoplasmsHumansProspective StudiesBiomarkersBiopsyBiomarkers, Tumor

Stichwörter der Autor:innen

Biomarkersdiagnostic odds ratiolung cancermetabolitesmicro-RNAsensitivityspecificity

Substanzen

MicroRNAsBiomarkersBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Pathology, Center of Traumatology and Major Burns, Ben Arous, Tunis, Tunisia.
  • University Tunis El Manar, Faculty of Medicine of Tunis, Tunisia.
  • Department of Biology, Military Hospital, Doha, Qatar.
  • Department of Thoracic Surgery, Abderrahman Mami Hospital, Tunis, Tunisia.
  • Ministry of Health, Tunis, Tunisia.

Zitieren

APA

Mlika, M., Zorgati, M. M., Abdennadher, M., Bouassida, I., Mezni, F., & Mrabet, A. (2024). The diagnostic performance of micro-RNA and metabolites in lung cancer: A meta-analysis. Asian Cardiovascular and Thoracic Annals. https://doi.org/10.1177/02184923231215538

Vancouver

Mlika M, Zorgati MM, Abdennadher M, Bouassida I, Mezni F, Mrabet A. The diagnostic performance of micro-RNA and metabolites in lung cancer: A meta-analysis. Asian Cardiovascular and Thoracic Annals. 2024. doi:10.1177/02184923231215538

BibTeX
@article{Mlika2024,
  author = {Mlika, Mona and Zorgati, Mohamed Majdi and Abdennadher, Mehdi and Bouassida, Imen and Mezni, Faouzi and Mrabet, Ali},
  title = {The diagnostic performance of micro-RNA and metabolites in lung cancer: A meta-analysis},
  journal = {Asian Cardiovascular and Thoracic Annals},
  year = {2024},
  doi = {10.1177/02184923231215538}
}
Kostenlos starten →